Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virgil Ejc Schijns

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Expert Review of Vaccines|September 5, 2008
New views on immunopotentiators in modern vaccinesVirgil Ejc Schijns, James M Brewer
Current Opinion in Immunology|August 20, 2023
Outer membrane vesicle-based intranasal vaccinesPeter Van der Ley, Virgil Ejc Schijns
The Permanente Journal|March 19, 2015
Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published ReportDaniela A Bota, Daniela Alexandru-Abrams, Chrystel Pretto, et al.
CNS Oncology|August 31, 2018
Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4<sup>+</sup> T-lymphocyte countsDaniela A Bota, Jinah Chung, Manisha Dandekar, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Expert Review of Vaccines|September 5, 2008
New views on immunopotentiators in modern vaccinesVirgil Ejc Schijns, James M Brewer
Current Opinion in Immunology|August 20, 2023
Outer membrane vesicle-based intranasal vaccinesPeter Van der Ley, Virgil Ejc Schijns
The Permanente Journal|March 19, 2015
Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published ReportDaniela A Bota, Daniela Alexandru-Abrams, Chrystel Pretto, et al.
CNS Oncology|August 31, 2018
Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4<sup>+</sup> T-lymphocyte countsDaniela A Bota, Jinah Chung, Manisha Dandekar, et al.
Pageof 1